| Structure-based classification predicts drug response in EGFR-mutant NSCLC JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ... Nature 597 (7878), 732-737, 2021 | 269 | 2021 |
| Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ... Journal of Thoracic Oncology 17 (3), 399-410, 2022 | 198 | 2022 |
| Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ... Journal for immunotherapy of cancer 9 (8), 2021 | 150 | 2021 |
| Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC L Hong, MV Negrao, SS Dibaj, R Chen, A Reuben, JM Bohac, X Liu, ... Journal of Thoracic Oncology 15 (9), 1449-1459, 2020 | 142 | 2020 |
| The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma M Zhuo, Y Guan, X Yang, L Hong, Y Wang, Z Li, R Chen, HA Abbas, ... Clinical Cancer Research 26 (4), 892-901, 2020 | 86 | 2020 |
| Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer Y Wang, Z Yu, T Wang, J Zhang, L Hong, L Chen Lung cancer 56 (2), 289-294, 2007 | 84 | 2007 |
| Expression of periostin in the serum of NSCLC and its function on proliferation and migration of human lung adenocarcinoma cell line (A549) in vitro L Hong, H Sun, X Lv, D Yang, J Zhang, Y Shi Molecular biology reports 37, 2285-2293, 2010 | 77 | 2010 |
| Overexpression of periostin predicts poor prognosis in non-small cell lung cancer LZ Hong, XW Wei, JF Chen, Y Shi Oncology letters 6 (6), 1595-1603, 2013 | 74 | 2013 |
| Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer N Coleman, L Hong, J Zhang, J Heymach, D Hong, X Le ESMO open 6 (6), 100319, 2021 | 70 | 2021 |
| The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer X Shen, L Hong, H Sun, M Shi, Y Song Oncology reports 22 (3), 535-539, 2009 | 69 | 2009 |
| Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer L Hong, J Zhang, JV Heymach, X Le Therapeutic Advances in Medical Oncology 13, 1758835921992976, 2021 | 50 | 2021 |
| Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer B Xia, LZ Hong, XW Cai, ZF Zhu, Q Liu, KL Zhao, M Fan, JF Mao, HJ Yang, ... International Journal of Radiation Oncology* Biology* Physics 91 (3), 517-523, 2015 | 44 | 2015 |
| Frequent KIT mutations in human gastrointestinal stromal tumors Z Xu, X Huo, C Tang, H Ye, V Nandakumar, F Lou, D Zhang, S Jiang, ... Scientific reports 4 (1), 5907, 2014 | 44 | 2014 |
| Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer L Hong, M Aminu, S Li, X Lu, M Petranovic, MB Saad, P Chen, K Qin, ... Nature communications 14 (1), 695, 2023 | 25 | 2023 |
| Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study MB Saad, L Hong, M Aminu, NI Vokes, P Chen, M Salehjahromi, K Qin, ... The Lancet Digital Health 5 (7), e404-e420, 2023 | 21 | 2023 |
| Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform Z Xu, X Huo, H Ye, C Tang, V Nandakumar, F Lou, D Zhang, H Dong, ... PloS one 9 (7), e100442, 2014 | 21 | 2014 |
| Antithrombin-Ⅲ without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase H Sun, L Hong, X Shen, X Lin, Y Song, Y Shi Chinese medical journal 122 (20), 2466-2471, 2009 | 20 | 2009 |
| MET amplification as a resistance driver to TKI therapies in lung cancer: clinical challenges and opportunities K Qin, L Hong, J Zhang, X Le Cancers 15 (3), 612, 2023 | 17 | 2023 |
| Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping X Le, L Hong, C Hensel, R Chen, H Kemp, N Coleman, CA Ciunci, SV Liu, ... JCO Precision Oncology 5, 1802-1812, 2021 | 17 | 2021 |
| Efficacy of targeted inhibitors in metastatic lung squamous cell carcinoma with EGFR or ALK alterations WE Lewis, L Hong, FE Mott, G Simon, CC Wu, W Rinsurongkawong, ... JTO Clinical and Research Reports 2 (11), 100237, 2021 | 17 | 2021 |
